MENU
NVO
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

NVO stock forecast, quote, news & analysis

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products... Show more

A.I.Advisor
published price charts
A.I.Advisor
Nov 02, 2026

Novo Nordisk (NVO) Stock Analysis: Can the Wegovy Pill Offset Pricing Pressure and a Patent Cliff?

Key Takeaways

  • Novo Nordisk (NVO) shares rose roughly 5.5% over the trailing 30 days, recovering to near $40 from a late-September low, though the stock remains well below its mid-2026 levels.
  • Over the past three months, shares have declined about 22%, pressured by pricing headwinds, intensifying competition, and a tepid investor reaction to the company's long-term growth plan.
  • The GLP-1 franchise — Ozempic, Wegovy, and the newly launched oral Wegovy — remains the core revenue engine, with the Wegovy pill showing strong early prescription uptake.
  • Management's 2026 guidance points to lower adjusted sales and operating profit, reflecting reduced realized prices and semaglutide patent expirations in certain markets.
  • Eli Lilly's tirzepatide-based products and U.S. drug-pricing policies are key competitive and regulatory headwinds shaping investor sentiment.
  • Explore Novo Nordisk's Price Targets, Earnings, and Forecast pages for additional data and forward-looking metrics.
  • Discover how AI-driven trading strategies are positioning across the market by exploring Trending AI Robots.

Current Market Snapshot

Novo Nordisk's American depositary receipts (ADRs) have stabilized in recent weeks after a prolonged de-rating. The stock closed near $40 in late October 2026, marking a modest recovery of roughly 5.5% from its late-September trough around $37. The rebound, however, follows a much steeper decline: shares traded near $51 in late July and have fallen roughly 22% over the trailing three months.

The longer-term picture is more sobering. After peaking in mid-2024 as Europe's most valuable company, Novo Nordisk's valuation has contracted sharply, with the stock trading well below its record highs. Investor sentiment has shifted from exuberance over the obesity drug boom to concern about pricing pressure, a looming patent cliff, and whether the company can defend its leadership against Eli Lilly and other rivals.

Novo Nordisk (NVO) Business Overview and Competitive Position

Novo Nordisk is a Denmark-based pharmaceutical company and a global leader in diabetes and obesity care. Its portfolio is anchored by semaglutide, the active ingredient behind Ozempic (injectable treatment for type 2 diabetes), Wegovy (injectable treatment for obesity and weight management), and Rybelsus (oral semaglutide). The company also markets a broad range of insulin products and a growing pipeline of next-generation therapies, including CagriSema, a combination candidate for obesity.

The GLP-1 category has driven Novo Nordisk's extraordinary growth in recent years, generating tens of billions of dollars in annual revenue and propelling the company to the top of European markets. Its competitive strengths include deep manufacturing capacity, a large installed patient base, and an expanding set of approved indications. At the same time, its heavy reliance on a single molecule — semaglutide — has become a key investor concern as competition intensifies and patent expirations approach.

Recent Developments Driving NVO

Several verified developments have shaped the stock over the past quarter. In early 2026, the company launched oral Wegovy in the United States, the first GLP-1 therapy available in pill form for weight management. The launch has been strong by prescription volume, with management citing millions of cumulative prescriptions and a large share of new users, supporting a series of modest upward revisions to its full-year outlook.

Those upgrades, however, have been framed within a declining base. Novo Nordisk guided to lower adjusted sales and operating profit for 2026, citing lower realized prices, reduced Medicaid obesity coverage, and the Most-Favored-Nations pricing framework in the U.S. The company also faces semaglutide patent expirations in several markets, including Canada, India, Brazil, and Turkey, with U.S. and European expirations expected in the early 2030s.

Competitive pressure from Eli Lilly remains central to the narrative. Lilly's tirzepatide-based Mounjaro and Zepbound have taken meaningful share in the diabetes and obesity markets. Novo Nordisk's CagriSema candidate also fell short of non-inferiority to tirzepatide in the REDEFINE 4 trial, tempering expectations for the next-generation pipeline.

In late September 2026, the company's Capital Markets Day drew a negative market reaction. Management outlined plans to launch at least five "multi-blockbuster" drugs and add more than $23 billion in new sales by 2030, but investors sought greater specificity on how growth would be delivered, and shares fell sharply on the announcement.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of top-performing automated trading strategies from a broader ecosystem of hundreds of AI-powered bots that trade thousands of tickers. Rather than listing every available bot, the section highlights those that are currently most relevant and strongest by performance. The robots vary widely in approach, holding timeframe, and risk profile, ranging from short-term momentum strategies to longer-term trend-following systems, each with its own performance metrics and track record. For investors seeking a data-driven complement to manual research, exploring the Trending AI Robots page can offer a useful view into how automated systems are positioning across the market.

2026 Outlook and What Investors Should Watch

Looking ahead, investors will focus on whether oral Wegovy can sustain its prescription momentum and offset continued price erosion in the core injectable franchise. The U.S. regulatory decision on CagriSema, expected in the fourth quarter of 2026, is another near-term catalyst, as are further updates on the company's broader cardiovascular and metabolic pipeline.

Key risks include the pace of semaglutide patent expirations, ongoing U.S. drug-pricing policy changes, and Lilly's continued market-share gains, including its own oral GLP-1 candidate. Macroeconomic and currency factors also matter, given the company's substantial exposure to the U.S. market and the translation effect on Danish kroner-denominated results. Management's ability to deliver on its 2030 growth plan while defending margins will be closely scrutinized in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for NVO with price predictions
Nov 16, 2026

NVO in upward trend: 10-day moving average crossed above 50-day moving average on November 11, 2026

The 10-day moving average for NVO crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on NVO as a result. In 55 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.

NVO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 203 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

The Aroon Indicator entered an Uptrend today. In 161 of 255 cases where NVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Bearish Trend Analysis

The 10-day RSI Indicator for NVO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 24 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 72 cases where NVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

NVO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (-1.421). P/E Ratio (1.534) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). Dividend Yield (0.046) settles around the average of (0.038) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (4.033).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

A.I.Advisor
published Dividends

NVO paid dividends on August 25, 2026

Novo-Nordisk A/S NVO Stock Dividends
А dividend of $0.58 per share was paid with a record date of August 25, 2026, and an ex-dividend date of August 17, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 4%. MIRA experienced the highest price growth at 2%, while SCLX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 32
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 25 (-100 ... +100)
Novo Nordisk (NVO) Stock Analysis: Can the Wegovy Pill Offset Pricing Pressure and a Patent Cliff?